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NEIVA S. L. GONÇALES,1 JOÃO RENATO R. PINHO,2* REGINA C. MOREIRA,2 CLÁUDIA P. SARACENI,2
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FERNANDO L. GONÇALES JÚNIOR3
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The seroprevalence of anti-hepatitis E virus (HEV) antibodies was investigated by enzyme immunoassay in
205 volunteer blood donors, 214 women who attended a center for anonymous testing for human immunode-
ficiency virus (HIV) infection, and 170 hospital employees in Campinas, a city in southeastern Brazil. The
prevalence of anti-HEV antibodies ranged from 2.6% (3 of 117) in health care professionals to 17.7% (38 of 214)
in women who considered themselves at risk for HIV. The prevalence of anti-HEV antibodies in health care
professionals was not significantly different from that in healthy blood donors (3.0%, 5 of 165) and blood
donors with raised alanine aminotransferase levels (7.5%, 3 of 40). The prevalence of anti-HEV antibodies
(13.2%, 7 of 53) in cleaning service workers at a University hospital was similar to that among women at risk
for HIV infection. These results suggest that HEV is circulating in southeastern Brazil and that low socioeco-
nomic status is an important risk factor for HEV infection in this region.
Hepatitis E virus (HEV) is considered the main etiologic
agent of enterically transmitted non-A, non-B hepatitis (ET-
NANBH) and occurs in epidemics or sporadically. ET-
NANBH, once thought to be a disease confined to developing
countries, is now recognized to have a wider geographical
distribution (12, 33). Epidemics have been related to contam-
inated water supplies, as fecal-oral transmission is the major
route of transmission (29). The symptoms of ET-NANBH are
similar to those of hepatitis A, although it affects primarily
young adult populations already immune to hepatitis A virus
(HAV). HEV is well recognized as a cause of fulminant he-
patic failure in areas where it is endemic (23), particularly in
pregnant women who contract it in the third trimester (10). In
developed countries, sporadic cases have been identified
among travelers from areas where it is endemic and HEV has
been implicated in some community-acquired cases of NANBH
in the United States and other western countries (12).
Until recently, the diagnosis of ET-NANBH was based on
serology after the exclusion of other viral hepatitis. In 1990, the
isolation of a partial cDNA clone from HEV (22) led to the
identification of type-common immunodominant epitopes and
the development of diagnostic serological assays for the detec-
tion of antibodies to recombinant HEV antigens (4).
The prevalence of HEV infection among blood donors in
developed countries ranges from 0.4 to 3.9% (4, 14, 15). An
association between HEV and hepatitis C virus infections has
been reported, suggesting similar or overlapping routes of
transmission (21). In addition, a higher prevalence of antibod-
ies to HEV has been reported among patients undergoing
chronic hemodialysis (9), suggesting that this virus is also
spread by the parenteral route. Homosexual men also have a
high prevalence of HEV infection (15), and the possibility of
sexual transmission cannot be neglected.
Few studies have addressed the prevalence of HEV infection
in Brazil because diagnostic tests for this illness have only
recently been available. HEV infection has already been de-
tected in the Amazon basin among gold miners (17) and iso-
lated communities (26). Acute viral hepatitis cases possibly
associated with HEV have been reported in central (27) and
northeastern Brazil (18, 19). In southeastern Brazil, HEV an-
tibodies have been detected in health care workers and dialysis
patients (6).
The aim of the present study was to determine the preva-
lence of HEV infection among blood donors and populations
with different risks of exposure to viral infections, such as
women attending a center for anonymous testing for human
immunodeficiency virus (HIV) infection (CAT-HIV) and em-
ployees working at the State University of Campinas hospital,
Campinas, São Paulo State, in southeastern Brazil.
MATERIALS AND METHODS
Population. A total of 589 samples collected in Campinas, São Paulo State,
Brazil, were analyzed. The samples were from individuals in three different
groups.
Group I. One hundred sixty-five volunteer blood donors with alanine amino-
transferase (ALT) levels ,2 times the upper normal value (129 [78.2%] male and
36 [21.8%] female; mean age, 33.9 6 10.1 years; range, 18 to 61 years; median,
32 years [group IA]) and 40 volunteer blood donors with ALT levels .2 times the
upper normal value (39 [90%] male and 4 [10%] female; mean age, 34.3 6 7.9
years; range, 21 to 54 years; median, 34 years [group IB]) were included. These
205 donors were all negative for the routinely screened markers of syphilis,
hepatitis B and C, HIV type 1 and 2 infections, human T-cell leukemia virus type
1 and 2 infections, and Chagas’ disease.
Group II. Two hundred fourteen women (mean age, 29.6 6 10.2 years; range,
14 to 71 years; median, 26 years) who attended a CAT-HIV were included in
group II, which was further divided into groups IIC (21 prostitutes) and IID (193
women who denied prostitution but considered themselves at risk for HIV
infection). Data on several variables (intravenous drug use [IVDU], previous
sexually transmitted disease [STD], practice of oral or anal sex, and anti-hepatitis
B core antigen and anti-hepatitis C virus [HCV] antibody status) possibly related
to a risk of viral transmission were collected from this population.
Group III. One hundred seventy employees working in the State University of
Campinas hospital (35 [20.5%] male and 135 [71.5%] female; mean age, 33.2 6
8.2 years; range, 20 to 53 years; median, 31 years). This group was further divided
into 117 health care workers (group IIIE) and 53 cleaning service workers (group
IIIF).
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Serology. Serum samples were stored at 220°C until tested for anti-HEV
immunoglobulin G (IgG) using an enzyme immunoassay (Abbott GmbH Diag-
nostika, Wiesbaden, Germany). This assay is based on two recombinant antigens
(SG-3 and 8-5) derived from different open reading frames of the Burmese strain
of HEV expressed as a CMP-2-keto-3-deoxyoctulosonic acid synthetase fusion
protein in Escherichia coli. Samples were tested in accordance with the manu-
facturer’s instructions, and those with absorbances less than the cutoff (CO)
value were considered negative. Samples with absorbance (S) greater than or
equal to the CO value were tentatively considered reactive and then retested in
duplicate to confirm the result. Results were recorded as S/CO ratios to allow
comparison of the intensity reactions of individual samples. The samples were
considered reactive when the S/CO ratio was higher than 1.0.
Antibodies to HCV were detected using a third-generation enzyme immuno-
assay (Abbott Laboratories, North Chicago, Ill.). Anti-HBc antibodies were
screened with a competitive enzyme immunoassay (Corzyme; Abbott Laborato-
ries).
Statistical analysis. Statistical comparison of distribution was carried out using
either the x2 or Fisher exact test, as applicable. For comparison of means and
variances, other tests were used (Student t, Kruskal-Wallis, and Mann-Whitney
tests). The level of significance was set at P , 0.05.
RESULTS
As shown in Table 1, the prevalence of anti-HEV IgG an-
tibodies was 4.0, 17.7, and 5.9% in groups I, II, and III, re-
spectively. The prevalence of anti-HEV IgG antibodies in
group II was significantly higher (P , 0.001) than in groups I
and III.
Anti-HEV IgG antibodies were found in 5 of 165 (3.0%) and
in 3 of 40 (7.5%) blood donors with ALT levels ,2 times
(group IA) and .2 times (group IB) the upper normal value,
respectively. The two groups had similar prevalences of anti-
HEV antibodies (P 5 0.1889).
Anti-HEV IgG was detected in 3 (14.2%) out of 21 prosti-
tutes and in 35 (18.1%) out of 193 women who denied prosti-
tution in group II. There was no statistically significant differ-
ence in the prevalence of anti-HEV between these two
populations (P 5 1.000).
In group III, the prevalence of anti-HEV IgG was signifi-
cantly different between the two subgroups: 3 of 117 (2.6%)
among health care workers but 7 of 53 (13.2%) among cleaning
service workers (P 5 0.0129).
The anti-HEV reactivity of sera from these populations was
also analyzed (Fig. 1). For blood donors, the mean S/CO ratio
was 0.352 6 0.229 (range, 0.040 to 1.890). For group II, the
mean S/CO ratio was 0.793 6 0.629 (range, 0.050 to 4.520). For
group III, the mean S/CO ratio was 0.499 6 0.369 (range, 0.150
to 2.480). The mean S/CO ratios were different among these
three groups (P , 0.001).
Considering only the anti-HEV antibody-positive samples,
the mean S/CO ratio of samples from blood donors (1.217 6
0.279) was significantly different from those found in groups II
(1.773 6 0.985; P 5 0.005) and III (1.757 6 0.541; P 5 0.016).
The mean S/CO ratios of positive samples from groups II and
III were not significantly different (P 5 0.947). Among the
negative samples, the mean S/CO ratios were significantly dif-
ferent among the three groups (group I, 0.317 6 0.141; group
II, 0.581 6 0.151; group III, 0.421 6 0.150; P , 0.001).
The variables possibly related to viral transmission among
women who attended the CAT-HIV are shown in Table 2. The
prevalence of anti-HEV antibodies was not significantly re-
lated to IVDU, previous STD, or practice of oral or anal sex.
Anti-HBc antibodies were detected in 36 of 214 (16.8%)
women tested, while anti-HCV antibodies were detected in 10
of 214 (4.7%) women tested. There was no significant associ-
ation between the detection of anti-HEV antibodies and sero-
logical markers of hepatitis B and C.
DISCUSSION
The overall prevalence of anti-HEV antibodies among blood
donors from Campinas (4%) was generally higher than that
reported in studies from developed countries (0.4 to 3.9%) (4,
13, 14). The anti-HEV antibody prevalence found in blood
donors from Campinas was similar to that reported for blood
donors from Salvador, Bahia, northeastern Brazil (2%; P 5
0.2590) (18). On the other hand, it was lower than that in
countries such as China, where a prevalence of 16% (P ,
0.001) was reported (13). Furthermore, recently published data
from another South American population, Bolivian blood do-
nors, showed a prevalence of 16.2% (93 of 574; P 5 0.00001)
(11). The large difference found in anti-HEV antibody preva-
lence reinforces the importance of studies involving other pop-
ulations from different geographical regions.
The prevalence of anti-HEV antibodies did not differ be-
tween blood donors with normal and raised ALT levels, sug-
gesting that HEV is not a common cause of raised ALT levels
in patients without markers of known viruses. Our results agree
with previous data showing that viral hepatitis is not a common
TABLE 1. Seroprevalence of anti-HEV IgG antibodies in
different populations
Group
No. (%) of persons




I 8 (4.0) 197 (96.0) 205 0.1889
IA 5 (3.0) 160 (97.0) 165
IB 3 (7.5) 37 (92.5) 40
II 38 (17.7) 176 (82.3) 214 1.0000
IIC 3 (14.2) 18 (85.8) 21
IID 35 (18.1) 158 (81.9) 193
III 10 (5.9) 160 (94.1) 170 0.0129
IIIE 3 (2.6) 114 (97.4) 117
IIIF 7 (13.2) 48 (86.8) 53
FIG. 1. Anti-HEV reactivity of sera from the different groups. Values are
expressed as S/CO ratios. Mean S/CO ratios 6 standard deviations are shown in
the bottom.
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cause of raised ALT levels in seronegative blood donors (8).
Only an IgM-specific assay can distinguish between acute and
past HEV infections (32), but it is noteworthy that anti-HEV
antibody-positive blood donors have a significantly lower mean
S/CO ratio (1.217 6 0.279) than the other groups. These pos-
itive IgG results probably reflect previous but not acute expo-
sure to the virus.
The prevalence of anti-HEV antibodies in blood donors
from Campinas was lower than that of anti-HAV antibodies
(20). This fact can be explained four different ways.
First, transmission of HEV seems to be less efficient than
that of HAV; as HEV appears to be extremely labile (1, 2)
while a major distinguishing feature of HAV is its exceptional
stability (24).
Second, the kinetics of anti-HEV antibody decay may be
different and some individuals previously infected may not be
detected. Controversial data have already been published: two-
thirds of pediatric cases became seronegative by 9 months in
one study, but another study showed positive cases in adults
infected 14 years before (3).
Third, there are no data on the time of introduction of HEV
into the local population. We may speculate that HEV was
introduced more recently in southeastern Brazil. Studies com-
paring viral RNA sequences from Brazilian isolates by phylo-
genetic analysis may be useful in addressing this point.
Fourth, currently commercial available kits for the detection
of anti-HEV IgG may not be sensitive enough to detect anti-
bodies directed to different epitopes expressed in some viral
proteins or only by some viral strains.
Further studies using recently developed anti-HEV kits and
involving follow-up of anti-HEV antibody-positive individuals
and the molecular characterization of circulating HEV geno-
types should be carried out to elucidate the role of these
hypotheses to explain these results.
The first anti-HEV kits were based on immunoreactive re-
gions located at open reading frames 2 and 3 (30). The assay
commercially available in our country also has peptide SG3 as
an antigen, leading to increased sensitivity since it contains two
additional epitopes (31). This assay has already been used
worldwide for epidemiological studies, but improved assays for
anti-HEV detection are still under development.
Recently, the accuracy of these assays has been improved
using other antigens, such as a mosaic protein containing short
antigenically reactive regions of the virus (5) or recombinant
proteins that have a conformational and immunological struc-
ture similar to that of native antigens (34). This last assay has
been shown to have higher sensitivity than the ones developed
first, especially concerning the detection of IgM antibodies
(32).
Only 3 (2.6%) out of 117 health care workers (doctors,
nurses, and laboratory staff) had anti-HEV antibodies, showing
that they do not constitute a risk group for HEV infection. On
the other hand, a statistically significantly higher prevalence (7
of 53 [13.2%]; P 5 0.0129) of anti-HEV antibodies was found
among cleaning service workers.
A statistically significantly higher prevalence of anti-HEV
antibodies was also found in women from group II (17.7%).
There was no difference in anti-HEV antibody frequency be-
tween the two subgroups (C and D) of these women. The
prevalence of anti-HBc (16.8%) and anti-HCV (4.7%) anti-
bodies among these women was higher than in blood donors (9
and 2.1%, respectively; P , 0.05) (7). This could reflect either
their socioeconomic status or their lifestyle, since exposure to
sexual or parenteral transmission is a known risk factor for
hepatitis B or C infection, respectively.
Anti-HEV antibodies have not been detected in a signifi-
cantly higher proportion in women positive for anti-HBc and
anti-HCV antibodies, which are surrogate markers of sexual
and parenteral risks of exposure, respectively. Furthermore,
the anti-HEV antibody results for these women showed no
significant correlation with risk factors previously associated
with HEV infection by other authors, such as IVDU (28) or
sexual promiscuity (16), measured by the number of partners
and previous STD. Sexual practices such as oral and anal sex,
which are potentially associated with transmission by the fecal-
oral route, were not associated with anti-HEV antibodies.
The overall prevalence among the cleaning service workers
(13.2%) in group IIIF was similar to that observed in group II
(P 5 0.4283), indicating that both populations have an in-
creased risk for HEV infection.
Groups II and III showed the highest mean S/CO ratio
compared to group I, suggesting that these groups probably
have a more recent contact with HEV, either as the first in-
fection or as an immunological booster. Only the specific de-
TABLE 2. Variables possibly related to HEV transmission among women attending a CAT-HIV
Variable Presence of variable
No. (%) of persons
Total P value
Anti-HEV antibody positive Anti-HEV antibodynegative
IVDU Yes 0 (0) 5 (100.0) 5 0.5886
No 38 (18.2) 171 (81.8) 209
STD Yes 4 (12.5) 28 (87.5) 32 0.6153
No 34 (18.7) 148 (81.3) 182
Oral sex Yes 22 (18.6) 96 (81.4) 119 0.7066
No 16 (16.7) 80 (83.4) 96
Anal sex Yes 16 (23.5) 52 (76.5) 68 0.1315
No 22 (16.7) 124 (84.9) 146
Anti-HBc antibodies Yes 9 (25.0) 27 (75.0) 36 0.2124
No 29 (16.3) 149 (83.7) 178
Anti-HCV antibodies Yes 3 (30.0) 7 (70.0) 10 0.3880
No 35 (17.2) 169 (82.8) 204
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tection of anti-HEV IgM antibodies could distinguish recent
from past HEV infections. No statistically significant difference
in the mean S/CO ratios was found between these two groups,
although samples with ratios higher than 3.00 were found only
in group II.
The commercially available enzyme-linked immunosorbent
assay kit detects specific anti-HEV IgG and therefore is useful
in diagnosing acute and past HEV infections. The recent de-
velopment of an HEV IgM enzyme-linked immunosorbent
assay was necessary to confirm acute HEV infection. Recently,
two new assays have been developed using either a mosaic
protein (5) or baculovirus-expressed antigens (32) but neither
of them is commercially available in our country.
Two explanations could account for the higher exposure to
HEV among groups II and IIIF compared to the other groups.
The more probable explanation is their socioeconomic status,
as cleaning service workers are generally recruited in poor,
peripheral districts from populations with a low socioeconomic
status, as well as most of the women who attended the CAT-
HIV. Another explanation is directly related to their lifestyle.
The activities of cleaning service workers make them more
prone to exposure to agents transmitted by the fecal-oral route.
Among the women who attended the CAT-HIV, we cannot
rule out other factors related to their behavior not analyzed
that might have contributed to the higher exposure to HEV.
The data presented here points to socioeconomic status as the
more likely hypothesis, but studies involving individuals of low
socioeconomic status not exposed to the same conditions as
groups II and IIIF are required to confirm it.
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7. Gonçales, F. L., Jr., R. J. Pedro, L. J. Silva, R. S. B. S. Boccato, and N. S. L.
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